IITRI NEWS
NEWS
We are ready to answer your questions and provide guidance.
News
Service Spotlight: Exposure Atmosphere Characterization
STARTING OFF ON THE RIGHT FOOT Our inhalation services include preliminary method development activities as the necessary first step for inhalation toxicology studies. The selection and characterization of the test atmosphere to be realistic and extensively measured...
SARS-CoV-2 Variants of Concern Now Available
IITRI now has access to multiple SARS-CoV-2 variants. Currently available: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma). Available soon: B.1.617.1 (Kappa) and B.1.617.2 (Delta) These variants are available for use in our assays (immunostain and neutralization) as well...
Immunostain SARS-CoV-2 Efficacy Assay Available
IITRI now offers an improved efficacy assay for looking at effects of drugs on SARS-CoV-2. Although this assay no longer includes a cytotoxicity readout, we offer a neutral red assay in BSl-2 instead if needed. This current assay uses immunostaining and provides more...
American College of Toxicology (Virtual) 41st Meeting
Even though we were saddened to hear that the 41st Annual Meeting of the American College of Toxicology (Nov 12-19) will not take place in the wonderful city of Austin this year, we support this decision and are very much looking forward to participating in the...
Hamster and ferret models available for COVID-19 studies
Ferret infection model: Since early in the pandemic, IITRI has been working on developing new animal models to test out therapeutics and treatments for COVID-19 (in addition to in vitro offerings of efficacy assays, neutralization assays, and surface decontaminant...
Promising antiviral activity of Moleculin’s drug candidate
IITRI is proud to share the promising news of one of our partners, Moleculin! Our team here at IITRI was contracted to perform additional in vitro testing of their drug candidate (WP1122) for antiviral effects against SARS-CoV-2. We used growth medium that more...
IITRI is testing antivirals and vaccines for COVID-19 | CRO
IITRI is now in custody of the a SARS-CoV-2 strain responsible for COVID-19. Our team is working on characterizing the strain for in vitro studies and in vivo modeling to test current vaccines and antivirals in addition to developing new treatments for this...
Dave McCormick Presenting at Science2Startup: New Drugs for Sleep Apnea
David McCormick has been selected to present on the development of novel agents to treat sleep-disordered breathing (SDB; sleep apnea) at the invitation-only Science2Startup (S2S)™ symposium on April 23, 2019, in Cambridge. The presenting group of 12 was...
IITRI-Vaccine-Antiinfectives-Lunch-n-Learn
IITRI-Vaccine-Antiinfectives-Lunch-n-Learn Title: Regulatory Approval Pathways for Vaccines and Antivirals: Laying the Groundwork Location: MassBio, 300 Technology Square, 8th Floor, Cambridge MA, 02139 Date/Time: Tuesday, September 25, 2018 Registration: 11 am...
Zika Poster Presentation at ASM Biothreats 2018 Meeting
IITRI will be presenting a poster at the ASM Biothreats 2018 Meeting, February 12-14 in Baltimore, MD. For more details, please contact us. Title: Humoral and cellular immune dynamics following Zika virus secondary challenge in non-human primates. Authors: J. M....
Recent Comments